Investor Relations

Company Profile

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The company’s lead product candidate, AT-001, is a novel aldose reductase inhibitor (ARI) that is being developed for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. Applied Therapeutics is also developing AT-007, a central nervous system penetrant ARI, for the treatment of Galactosemia, a rare pediatric metabolic disease. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy.

News Releases

Dec 16, 2019
Applied Therapeutics to Ring Nasdaq Closing Bell on December 17th
NEW YORK , Dec. 16, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (Nasdaq:APLT), announced today that Shoshana Shendelman , Ph.D., Founder, Chief Executive Officer and Chair of the Board, will ring the Nasdaq Closing Bell on Tuesday, December 17, 2019 , at 4:00 p.m. ET .
Dec 06, 2019
Applied Therapeutics Announces Presentation of Pre-Clinical Data Highlighting AT-001 for Treatment of Diabetic Cardiomyopathy at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
NEW YORK , Dec. 06, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the presentation of data at

Presentations

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.